Apeloa Pharmaceutical (SHE:000739) signed a strategic cooperation framework agreement for the outsourced customized production (CDMO) project.
Under the agreement, the pharmaceutical company and Jixing Hong Kong will continuously improve product market competitiveness and stable supply capabilities, and share benefits, according to a Friday filing with the Shenzhen bourse.
Apeloa Pharmaceutical will carry out the research and development and production of the CDMO project based on the parties' master service agreement.
Shares of the company rose 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.